Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

NCT00058019 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

51

Enrollment

NIH

Sponsor class

Conditions

Anaplastic Large Cell Lymphoma
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma

Interventions

DRUG: ixabepilone

Sponsor

National Cancer Institute (NCI)